 | |
 |
|
| Date | Title | | | 05/17/10 | ARCA Announces Special Protocol Assessment Agreement with FDA for
Bucindolol Development in Genotype-Defined Heart Failure Population| BROOMFIELD, Colo., May 17, 2010 (BUSINESS WIRE) --ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has reached
agreement with the U.S. Food and Drug Administration (FDA) regarding a
Special Protocol Assessment (SPA) on the design of a clinical trial to
assess the safety and efficacy of bucindolol in approximately 3,200
patients with chronic heart failure who have the genotype that appears
to respond most favorably to bucindolol. Bucindolol is th... |
|  | | 05/13/10 | ARCA Regains NASDAQ Listing Compliance| BROOMFIELD, Colo., May 13, 2010 (BUSINESS WIRE) --ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company
developing genetically targeted therapies for heart failure and other
cardiovascular disease, today announced that it received notification
from the NASDAQ Stock Market that the Company has demonstrated
compliance with the minimum stockholders' equity requirement for the
NASDAQ Global Market set forth in Listing Rule 5450(b)(1)(A) and that
... |
| | | 04/01/10 | ARCA biopharma Raises $6.8 Million in First Quarter of 2010 Through
At-The-Market Offering of Common Stock| BROOMFIELD, Colo., Apr 01, 2010 (BUSINESS WIRE) --ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically targeted therapies for heart failure and other
cardiovascular diseases, today announced that during the first quarter
of 2010, through its previously established equity distribution
agreement, it raised net proceeds of approximately $6.8 million through
the sale of 1,075,000 shares of ARCA common stock in open market.
... |
| | | 03/26/10 | ARCA biopharma Announces Patent Issued for Treating Heart Failure
Patients with Bucindolol Based on Genetic Testing| Revised Request for FDA Special Protocol Assessment for GencaroTM Development in Genotype-defined Heart Failure Population SubmittedBROOMFIELD, Colo., Mar 26, 2010 (BUSINESS WIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically targeted therapies for heart failure and other
cardiovascular diseases, today announced that the U.S. Patent and
Trademark Office (USPTO) has issued a patent on methods of treating
heart failure pa... |
| | | 03/17/10 | ARCA Announces Receipt of NASDAQ Notice per NASDAQ Rule 5810(b)| BROOMFIELD, Colo., Mar 17, 2010 (BUSINESS WIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company
developing genetically targeted therapies for heart failure and other
cardiovascular disease, today announced, as required by NASDAQ
Marketplace Rule 5810(b), that on March 12, 2010, it received a notice
from the NASDAQ Stock Market indicating that the Company's stockholders'
equity as of December 31, 2009, did not meet the minimum requiremen... |
| | | 03/10/10 | ARCA Announces Going Concern Opinion per Nasdaq Rule 5250(b)(2)| BROOMFIELD, Colo., Mar 10, 2010 (BUSINESS WIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company
developing genetically targeted therapies for heart failure and other
cardiovascular disease, today announced, as required by NASDAQ
Marketplace Rule 5250(b)(2), that the report of the Company's
independent registered public accounting firm, included in its
previously filed consolidated financial statements for the fiscal year
ended D... |
| | | 01/20/10 | ARCA Announces Publication of Bucindolol Data in Circulation: Heart Failure| Data from the Clinical Study BEST Indicate That in the Study Norepinephrine Lowering and Clinical Therapeutic Responses to Bucindolol Were Strongly Influenced by alpha-2C-Adrenergic Receptor GenotypeData Suggest Potential Use of Genetic Biomarkers to Define Which Patients Are Most Likely to Respond to the Pharmacologically Unique Beta-Blocker BucindololBROOMFIELD, Colo., Jan 20, 2010 (BUSINESS WIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing geneticall... |
| | | 01/11/10 | ARCA biopharma Receives Notice of Allowance for Patent for Treating Heart Failure Patients with Bucindolol Based on Genetic Testing| BROOMFIELD, Colo., Jan 11, 2010 (BUSINESS WIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically targeted therapies for heart failure and other
cardiovascular diseases, today announced that it has received a Notice
of Allowance from the U.S. Patent and Trademark Office (USPTO) for its
U.S. Patent Application Number 11/226,908 entitled "Methods for
Treatment with Bucindolol Based on Genetic Targeting." The Notice of... |
| |
|
| | | |
